BA
NTLA icon

Bridgewater Associates’s Intellia Therapeutics NTLA Stock Holding History

Bridgewater Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-223,166
Closed -$2.01M – 1159
2025
Q4 		$2.01M Buy
+223,166
New +$3.07M 0.01% 767
2023
Q1 		– Sell
-9,387
Closed -$328K – 841
2022
Q4 		$328K Buy
+9,387
New +$446K ﹤0.01% 763
2022
Q2 		– Sell
-4,907
Closed -$357K – 1045
2022
Q1 		$357K Buy
+4,907
New +$416K ﹤0.01% 923

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return